Corcept Therapeutics (CORT) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Corcept Therapeutics Announces First Quarter 2015 Results and Provides Corporate Update
May 7, 2015 4:06 PM EDTMENLO PARK, CA -- (Marketwired) -- 05/07/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT)
Per-share net loss in first quarter narrows to $0.05, from $0.14 in the same period last year First quarter revenue is $10.1 million, compared to $4.4 million in the first quarter 2014, a 129 percent increase $17.2 million generated from exercise of warrants Patient dosing underway in efficacy portion of Phase 1/2 trial of Korlym to treat triple-negative breast cancer (TNBC); results expected by the end of 2015 Next-generation selective GR antagonist CORT125134 is well-tolerated and functionally active in Phase 1 and is expected to enter Phase 2 in... More